Human Oncology & Pathogenesis Program

The Katharine Hsu Lab

Share
Back to top

Research

Katharine C. Hsu, MD, PhD
Katharine C. Hsu, MD, PhD
Professor of Medicine

My laboratory studies the natural killer (NK) cell and the molecules that control its ability to recognize and kill cancer and virally infected cells. Improved understanding of how NK cells behave is critical to advancing our ability to harness their innate capacity for tumor recognition and eradication. Therefore, an important component of my research focuses on the basic biology of the NK cell, identifying the molecules involved in controlling NK reactivity, and determining the laboratory and clinical conditions under which NK activity can be modified.

View Lab Overview

The Katharine Hsu Lab

Featured News

Katharine Hsu and Rosa Sottile
Unusual Immune Cell Type Could Be Good Target for Immunotherapy

Part natural killer, part T cell, this hybrid immune cell has a “double sword” for fighting cancer.
Katharine Hsu
Dr. Katharine Hsu Named Director of Tri-Institutional M.D.-Ph.D. Program

In her new role, Dr. Hsu will work to diversify matriculating classes and train students to become skilled leaders as both clinicians and biomedical researchers.
In the Lab
Pictured: Natural Killer Cells & Cancer Cell
Study Suggests Refined Donor Selection Could Improve Outcomes of Bone Marrow Transplantation in Leukemia

In the future, more-advanced genetic testing might offer better ways to match up patients who need a bone marrow transplant with potential donors.

Publications

Wu Z, Park S, Lau CM, Zhong Y, Sheppard S, Sun JC, Das J, Altan-Bonnet G, Hsu KC. Dynamic variability in SHP-1 abundance determines natural killer cell responsiveness. Sci Signal. 2021 Nov 9;14(708):eabe5380. doi: 10.1126/scisignal.abe5380. Epub 2021 Nov 9.

Wu Z, Lau CM, Sottile R, Le Luduec JB, Panjwani MK, Conaty PM, Srpan K, Laib Sampaio K, Mertens T, Adler SP, Hill AB, Barker JN, Cheung NV, Sun JC, Hsu KC. Human Cytomegalovirus Infection Promotes Expansion of a Functionally Superior Cytoplasmic CD3+ NK Cell Subset with a Bcl11b-Regulated T Cell Signature. J Immunol. 2021 Nov 15;207(10):2534-2544. doi: 10.4049/jimmunol.2001319. Epub 2021 Oct 8. PMCID: PMC8578400.

Sottile R, Panjwani MK, Lau CM, Daniyan AF, Tanaka K, Barker JN, Brentjens RJ, Sun JC, Le Luduec JB, Hsu KC. Human cytomegalovirus expands a CD8+ T cell population with loss of BCL11B expression and gain of NK cell identity. Sci Immunol. 2021 Sep 24;6(63):eabe6968. doi: 10.1126/sciimmunol.abe6968. Epub 2021 Sep 24.

Schetelig J, Baldauf H, Koster L, Kuxhausen M, Heidenreich F, de Wreede LC, Spellman S, van Gelder M, Bruno B, Onida F, Lange V, Massalski C, Potter V, Ljungman P, Schaap N, Hayden P, Lee SJ, Kröger N, Hsu K, Schmidt AH, Yakoub-Agha I, Robin M. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia. Front Immunol. 2021 Jan 19;11:584520. doi: 10.3389/fimmu.2020.584520. PMCID: PMC7851088.

Boudreau JE, Giglio F, Gooley TA, Stevenson PA, Le Luduec JB, Shaffer BC, Rajalingam R, Hou L, Hurley CK, Noreen H, Reed EF, Yu N, Vierra-Green C, Haagenson MD, Malkki M, Petersdorf EW, Spellman S, Hsu KC. KIR3DL1/HLA-B subtypes govern AML relapse after hematopoietic cell transplantation. J Clin Onc. 2017. 35(20):2268-2278.

View All Publications

People

Katharine C. Hsu, MD, PhD

Katharine C. Hsu, MD, PhD

Professor of Medicine

  • Physician-scientist Katharine Hsu studies the biology of human natural killer cells and how they contribute to disease processes.
  • MD, PhD, Cornell University Medical College
[email protected]
Email Address
646-888-2667
Office Phone
View physician profile
Physician profile

Members

Jean-Benoit Le Luduec, PhD
Jean-Benoit Le Luduec

Research Associate

Mohammed Kazim Panjwani
Mohammed Kazim Panjwani

Research Fellow

Gabryelle Kolk
Gabryelle Kolk

Research Technician

Theodota Kontopoulos
Theodota Kontopoulos

Senior Research Technician

Clara Lawry
Clara Lawry

Research Teach

Kyle Lupo
Kyle Lupo

Research Fellow

Brian Shaffer
Brian Shaffer

Assistant Attending

Sanam Shahid
Sanam Shahid

Clinical Fellow

Katja Srpan
Katja Srpan

Research Scholar

Lab Alumni
Jeanette Boudreau

Postdoctoral Fellow

Meighan Gallagher

Senior Research Technician

Yuchun Nie

Postdoctoral Fellow

Nidale Tarek

Pediatric Oncology Fellow

Farnoush ali-Abarghoui

Oncology Fellow

Knarik Arkun

Technician

Christine Camacho

Sr. Research Technician

Peter Conaty
Peter Conaty

Research Technician

Chris Forlenza

Pediatric Oncology Fellow, St. Baldrick’s Foundation Fellowship

Anupa Kudva
Xiao-Rong Liu

Senior Research Scientist

Guido Molina
Tiernan Mulrooney
Nabila Noor

Technician

Fabiana Ostronoff

Medical Resident

Soo Park

Sr. Research Technician

Rosa Sottile

Research Fellow

Lavanya Sundararajan

Post-doctoral Fellow

Kattria van der Ploeg
Kattria van der Ploeg

Post-doctoral Fellow

Jeff Venstrom

Clinical Oncology Fellow

Zeguang Wu, PhD
Zeguang Wu

Post-doctoral Fellow

Junli Yu

Post-doctoral Fellow

Xiangyu Zhao
Yao Chen

Clinical Fellow

Giglio Fabio

Visiting BMT Fellow

Lab Affiliations

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Katharine C. Hsu discloses the following relationships and financial interests:

  • American Society for Blood and Marrow Transplantation (ASBMT)
    Fiduciary Role/Position
  • Wugen, Inc.
    Provision of Services (uncompensated)

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures